Company Presentation

April 2021

A subsidiary of

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward- looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

2 All rights reserved to Canonic Ltd. ©

INTRODUCTION

3

Company Overview

  • Canonic was established in early 2019 as a spin-offfrom Evogene (NASDAQ, TASE: EVGN) focusing on medical cannabis
  • Canonic has an exclusive license to develop cannabis varieties using Evogene's state-of-the-artcomputational genomics technology
  • Distinct advantage to tackle market challenges by mapping, decoding and stabilizing the cannabis genetics
  • Breeding infrastructure among the biggest in Israel and unique proprietary knowhow
  • First generation varieties expected to produce premium quality products to connect the company with the patients and market
  • Product launch expected at early 2022- the company is evaluating its first-generation varieties with licensed growers and in preparation for commercial cultivation
  • Company products expected to be launched under the "Canonic" brand in Israel followed by the EU and NA with local partners
  • Next generation products expected to focus on 2 major medical indications, pain and inflammation that are >60% of the

medical market*

*Company estimate, based on data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

4 All rights reserved to Canonic Ltd. ©

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on novel cannabis varieties, for optimized therapeutic impact

We are here because genetics can make cannabis much more effective

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Evogene Ltd. published this content on 19 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 April 2021 14:36:04 UTC.